Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Novartis

Status: Completed

Conditions: Cardiovascular Disease and Lipoprotein(a)

Treatments: Diagnostic Test: Blood draw for Lp(a)

Study type: Interventional

Funder types: Industry

Identifiers

NCT03887520

CTQJ230A12001

2018-003786-34 (EudraCT Number)

Details and patient eligibility

About

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

Enrollment: 49,001 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent

• Established CVD defined as one of the following:

  • History of a myocardial infarction (MI) ≥3 months and ≤10 years before the study visit
  • History of ischemic stroke ≥ 3 months and ≤ 10 years before the study visit
  • Symptomatic PAD (intermitted claudication with ankle-brachial index ≤0.90 and/or lower limb amputation or re-vascularization due to lower limb ischemia

Exclusion criteria

• Patients currently enrolled in clinical studies with investigational drugs

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

49,001 participants in 1 patient group

Cardiovascular disease

Other group

Description:

Patients with established Cardiovascular disease

Treatment:

Diagnostic Test: Blood draw for Lp(a)